IN8bio Inc (INAB) concluded trading on Thursday at a closing price of $0.13, with 17.82 million shares of worth about $2.32 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -60.09% during that period and on May 15, 2025 the price saw a loss of about -9.68%. Currently the company’s common shares owned by public are about 81.26M shares, out of which, 71.27M shares are available for trading.
Stock saw a price change of -21.08% in past 5 days and over the past one month there was a price change of -18.81%. Year-to-date (YTD), INAB shares are showing a performance of -48.48% which decreased to -87.01% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $1.74 during that period. The average intraday trading volume for IN8bio Inc shares is 1.24 million. The stock is currently trading -20.64% below its 20-day simple moving average (SMA20), while that difference is down -28.77% for SMA50 and it goes to -57.10% lower than SMA200.
IN8bio Inc (NASDAQ: INAB) currently have 81.26M outstanding shares and institutions hold larger chunk of about 22.00% of that.
The stock has a current market capitalization of $12.03M and its 3Y-monthly beta is at 0.18. It has posted earnings per share of -$0.49 in the same period. It has Quick Ratio of 4.30 while making debt-to-equity ratio of 0.31. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INAB, volatility over the week remained 9.84% while standing at 7.91% over the month.
Analysts are in expectations that IN8bio Inc (INAB) stock would likely to be making an EPS of -0.06 in the current quarter, while forecast for next quarter EPS is -0.05 and it is -0.21 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.07 which is -0.05 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.19 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 63.86% while it is estimated to decrease by -3.88% in next year. EPS is likely to grow at an annualized rate of 23.77% for next 5-years, compared to annual growth of -13.22% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Laidlaw on March 18, 2024 offering a Buy rating for the stock and assigned a target price of $7.50 to it. Coverage by H.C. Wainwright stated IN8bio Inc (INAB) stock as a Buy in their note to investors on August 30, 2022, suggesting a price target of $14 for the stock.
